IMGN News and Press, ImmunoGen Inc. From 08/17/23

2023-08-17 06:40:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech...

2023-08-15 11:40:24 ET Summary Generating high yields while taking on less market risk is possible. Our Advanced cash covered put selling strategy can generate high double-digit yields with being very conservative with risk. I believe that selling put options capitalizes on ma...

2023-08-09 08:56:03 ET Summary ImmunoGen specializes in antibody-drug conjugates for cancer treatment, showing strong Q2 2023 financials with revenues of $83.15M. With over $75 million in net sales for Elahere, robust balance sheet, and growth trajectory, the company seems well-po...

2023-07-31 12:38:07 ET ImmunoGen Inc. (IMGN) Q2 2023 Earnings Conference Call July 31, 2023 8:00 am ET Company Participants Mark Enyedy - President, Chief Executive Officer Renee Lentini - Chief Financial Officer (interim), Chief Accounting Officer Isabel Kalofon...

2023-07-31 08:37:42 ET China Natural Resources ( NASDAQ: CHNR ) +49% . Allarity Therapeutics ( ALLR ) +31% . Barnes & Noble Education ( BNED ) +17% . Spero Therapeutics ( SPRO ) +13% Announces Special Protocol Assessment Agreement with FDA...

2023-07-31 06:55:31 ET ImmunoGen ( NASDAQ: IMGN ) announced that Anna Berkenblit, MD, Senior VP and chief medical officer, is stepping down from her position to take a hiatus prior to pursuing new opportunities outside of ImmunoGen. Dr. Berkenblit will continue with t...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved ...

2023-07-31 06:31:54 ET ImmunoGen press release ( NASDAQ: IMGN ): Q2 GAAP EPS of -$0.02 beats by $0.12 . Revenue of $83.15M (+485.6% Y/Y) beats by $36.55M . Total revenues were $83.2 million for the quarter ended June 30, 2023, including $77.4 million of net pro...

Continued Strong Momentum with ELAHERE Launch in US; Net Sales of $77.4 Million in Q2 Presented Positive Results for ELAHERE from Phase 3 MIRASOL Trial During Late-Breaking Oral Presentation at ASCO; First Therapy to Demonstrate an Overall Survival Benefit Compared to Chemotherapy in a Ph...

2023-07-28 11:55:37 ET ImmunoGen ( NASDAQ: IMGN ) is scheduled to announce Q2 earnings results on Monday, July 31st, before market open. The consensus EPS Estimate is -$0.15 (+37.5% Y/Y) and the consensus Revenue Estimate is $46.6M (+228.2% Y/Y). Over the last 2 years,...